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Purpose: During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks
to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient
resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to
evaluate prostate radiation therapy management decisions.
Methods and Materials: Radiation oncologists from the United States and the United Kingdom rapidly conducted a systematic review
and agreed upon recommendations to safely manage patients with prostate cancer during the COVID-19 pandemic. A RADS framework
was created: remote visits, and avoidance, deferment, and shortening of radiation therapy was applied to determine appropriate
approaches.
Results: Recommendations were provided by the National Comprehensive Cancer Network risk group regarding clinical node-positive,
postprostatectomy, oligometastatic, and low-volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return
visits were recommended when resources/staff available. Delays in consultations and return visits of between 1 and 6 months were
deemed safe based on stage of disease. Treatment can be avoided or delayed until safe for very low, low, and favorable
intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node-positive, recurrence postsurgery, oligometastatic,
and low-volume M1 disease can receive neoadjuvant hormone therapy for 4 to 6 months as necessary. Ultrahypofractionation isSources of support: This work had no specific funding.
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2 N.G. Zaorsky et al Advances in Radiation Oncology: --- 2020preferred for localized, oligometastatic, and low-volume M1, and moderate hypofractionation is preferred for postprostatectomy and
clinical node positive disease. Salvage is preferred to adjuvant radiation.
Conclusions: Resources can be reduced for all identified stages of prostate cancer. The RADS (remote visits, and avoidance, deferment,
and shortening of radiation therapy) framework can be applied to other disease sites to help with decision making in a global pandemic.
 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Cancer treatment in the era of COVID-19 requires
consideration of risks and benefits for patients and staff.1
Recent data suggest patients who have cancer are at
increased risk of infection and serious complications from
COVID-19.1 Although the American Society of Clinical
Oncology has provided resources for patients receiving
systemic therapy (https://www.asco.org/asco-coronavirus-
information), there remains minimal granular guidance on
the delivery of outpatient radiation therapy. Radiation
therapy is delivered to nearly 50% of patients with cancer,
a particularly vulnerable group given their older age,
frequent comorbidities, and underlying cancer diagnosis.2
Prostate cancer is frequently treated with radiation. It is
the most common solid tumor in men; it is a heterogeneous
disease for which timely therapy is indicated for some cases
and watchful waiting, active surveillance, or deferral of
treatment could be acceptable for others.3,4 Given the cur-
rent epidemic crisis, delaying radiation therapy treatment
(which requires multiple visits to health care facilities) for
patientswith prostate cancermay potentially reduce the risk
of iatrogenic exposure to COVID-19.
At the health care system level, when clinically appro-
priate, reducing visits conserves limited hospital resources
(eg, personal protective equipment [PPE]) for use by health
care workers who will have to care for the potentially vast
number of hospitalized patients with COVID-19. The de-
cision to delay life-saving cancer treatment in a time of a
resource-intensive pandemic represents a clinical conun-
drum without modern precedent. In these exigent circum-
stances, guidelines for managing patients who present with
prostate cancer would be valuable for the practicing clini-
cian. This article attempts to provide guidance based on
rapid expert opinion regarding how tomanage patients with
prostate cancer requiring radiation therapy during the
COVID-19 pandemic.
Methods and Materials
Given the swiftly evolving clinical knowledge sur-
rounding COVID-19 and the potential impact on radiation
oncology departments worldwide, we performed a rapid
review of evidence assessing the management of localized
prostate cancer with radiation therapy. The goal of this
rapid review was to synthesize knowledge to provide aframework for clinical practice and management of
prostate cancer during the COVID-19 pandemic, but this
framework could similarly be applied in any resource-
constrained setting or other disease type.
Within this framework we sought to answer these key
questions:
1. Which patients can have in-person clinic visits
safely delayed or converted to telehealth visits?
2. Which patients can safely avoid treatment or have
treatment deferred, and for how long?
3. Which patients can have radiation therapy safely
deferred with the initiation of androgen deprivation
therapy, and for how long?
4. For patients undergoing treatment, what are the
preferred treatment modalities and fractionation
schedules by disease risk?
To answer these questions, we assessed systematic
reviews, national guidelines, results from randomized
clinical trials, and treatment arms in ongoing randomized
trials assessing radiation therapy for prostate cancer.
Studies were required to be published in English between
January 1990 and March 2020. Results published only in
abstract form were limited to the period between January
1, 2015 and March 15, 2020. This literature search was
performed using MEDLINE via PubMed only. Dual
screening of the literature for inclusion was performed by
W.C.J. and D.E.S. to minimize the risk of selection bias
and was performed over the course of 3 hours.
Importantly, these recommendations apply only to
patients not infected with COVID-19. For patients who
have symptoms concerning for COVID-19, or who have
tested positive, please follow local hospital plans and
procedures.
In generating these recommendations, the following
assumptions were made: (1) the pandemic will last for
multiple months, often occurring in multiple waves with
variable peaks of severity; (2) during the pandemic, a
significant proportion of staff will not be available to
work (eg, because of illness, quarantine, family re-
sponsibilities from school closures); (3) capacity of hos-
pital services will be exceeded and stress the hospital
system; and (4) available staff will be deployed to
essential services. Ultimately, the combined effect is that
resources will be stressed and normal workflow will not
be possible.
Figure 1 The remote visits, and avoidance, deferment, and shortening of radiation therapy (RADS) framework.
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The RADS (remote visits, and avoidance, deferment,
and shortening of radiation therapy) framework was
developed and applied for all prostate cancer disease
states commonly treated with radiation therapy (Fig 1).
Table 1 summarizes the group’s recommendations for
each disease stage and according to visit type, simulation,
fiducial marker and rectal spacer placement, and treatment
itself. In all scenarios, the visits, procedures, and treat-
ment can safely be delayed by variable durations based on
stage of disease.
Remote visits
All visits should be transitioned to telehealth visits.
Although video visits are preferred, these telehealth
visits can include simple phone calls if video visits are
not possible given the limitations of technological
infrastructure at select centers. Very few patients with
prostate cancer require an in-person visit during a
pandemic, and the minimal value of a digital rectal ex-
amination is less important than the risk of COVID-19
exposure to patients and staff. Based on your institu-
tional resources and legal requirements, on-treatment
visits can also be performed using telehealth technology
to further reduce exposure risk. For patients who must
be seen in clinic, consideration should be given to
having patients wait in their cars or outside the facility
before their appointment to promote social distancing,
given high surface stability of COVID-19.5 Additionally,
the number of people accompanying patients should be
reduced to a minimum. Laboratory testing (eg, prostate-specific antigen [PSA] testing) should be performed in
settings with minimal contact with staff or other patients,
preferably outside of a busy hospital setting if possible.
Routine PSA testing posttreatment can safely be deferred
by 3 months in most instances.
Avoidance of radiation therapy
Generally, for very low-, low-, and favorable
intermediate-risk disease, treatment deferral until after
pandemic-related restrictions have been lifted was thought
to be safe. This advice is based on multiple clinical trials
demonstrating that these patients have very favorable
outcomes with watchful waiting, active monitoring, or
active surveillance.6,7 This is reflected in national guide-
lines that recommend broad use of active surveillance for
very low- and low-risk prostate cancer and selective use
in favorable intermediate-risk disease.4 The safety of
avoidance presumes that the pandemic will wane over the
next 12 months.
Deferral of radiation therapy
Patients with unfavorable intermediate-risk, high-risk,
very high-risk, postprostatectomy, clinical node-positive,
oligometastatic, and low-volume M1 can variably delay
in-person new patient consultations and return visits, but
these should be converted to timely remote telehealth
visits. After these patients have initiated treatment,
androgen deprivation therapy (ADT) can allow for further
deferral of radiation therapy as necessary based on the
nature of the ongoing epidemic.8,9 If ADT cannot be
delivered (eg, absolute patient refusal, supply exhausted,
Table 1 Recommendations
Disease state Visits Simulation/preparation If treatment is warranted during pandemic
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FIR Delay 3 mo Delay until
safe
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Do not use






























Delay 4-6 mo if
ADT
given
















Delay 4-6 mo if
ADT
given








































Delay 3 mo - - If symptomatic
do not delay
































Abbreviations: ADT Z androgen deprivation therapy; AS Z Active surveillance; EBRT Z external beam radiation therapy; FIR Z favorable intermediate risk; fx Z
fractions; Nþ Z regional lymph node involvement; PSA Z prostate-specific antigen; RT Z radiation therapy; RV Z return visit; SBRT Z stereotactic body radiation
therapy; UIR Z unfavorable intermediate risk.
* New consults and return visits can be delayed as necessary based on resource availability. If staff is able to conduct these visits without affecting pandemic response
resources, these should continue on a regular schedule using remote visits. PSA and other laboratory testing should be deferred as deemed safe. Return visit delay listed is
an additional delay beyond the current return visit interval.
y Placement of fiducial markers and rectal spacers requires extra personal protective equipment use. The benefit of these procedures should be based on resource and
staff availability.
z Brachytherapy should cautiously be used during the pandemic given high personal protective equipment requirements and resource utilization. Avoidance of
general anesthesia is preferred if possible.
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tients with rapid PSA doubling times (3 months) the
benefits of immediate treatment during a window of po-
tential cure must be weighed against the risk of COVID-
19 exposure and subsequent morbidity and mortality (eg,
age, comorbidities, immunosuppression).
ADT should not be used in disease states that have not
been shown to derive survival benefits (very low-, low-,
and favorable intermediate-risk disease). Significant pro-
longation of ADT beyond standard of care should be
avoided given the potential for increased morbidity and
other-cause mortality.10-12
It was agreed, based on recently presented evidence
from RadiotherapydAdjuvant Versus Early Salvagetrial13 and Radiation Therapy and Androgen Deprivation
Therapy in Treating Patients Who Have Undergone Sur-
gery for Prostate Cancer (NCT00541047) in 2019, that
early salvage radiation therapy is preferred over adjuvant
radiation therapy in all scenarios during a pandemic.Shortening of radiation therapy
If treatment is deemed necessary and safe, the shortest
fractionation schedule that has evidence of safety and
efficacy should be adopted. For localized prostate cancer,
5- to 7-fraction stereotactic body radiation therapy
(SBRT)/ultrahypofractionation should be used, which is
Figure 2 Workflow of prostate stereotactic body radiation therapy (SBRT). Please see Appendix E1 for more details on dose
constraints.
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Cancer Network guidelines as an acceptable regimen for
intermediate- and high-risk prostate cancer. A simplified
schema to help providers perform SBRT is shown in
Figure 2. For centers without the ability to perform image
guidance (cone beam computed tomography with or
without fiducial markers), a 20-fraction regimen can be
used to 60 to 62 Gy.14,15 For patients who are post-
prostatectomy, a moderate hypofractionated regimen of
20 fractions to 52.5 Gy is preferred (NCT00541047).16
For low-volume M1 disease, either SBRT or 6 Gy  6
fractions as used in the Systemic Therapy in Advancing or
Metastatic Prostate Cancer: Evaluation of Drug Efficacy
arm H is safe and acceptable.17 Dose constraints are
provided in Appendix E1 for the aforementioned
regimens.
Nonessential procedures that do not have evidence to
support their impact on overall survival rates, such as a
prostate magnetic resonance imaging (MRI), fiducial
markers, and/or rectal spacers, should be used very
selectively given they require either prolonged or extra
patient visits. These can variably be considered if deemed
necessary to perform prostate SBRT to expedite treat-
ment; however, prostate SBRT can safely be performed
without all of these additional procedures if necessary (eg,
HYPOfractionated RadioTherapy of intermediate risk
localised Prostate Cancer trial used 3-dimentional
conformal radiation therapy with large 7 mm clinical
target volume to planning target volume margins, did notuse rectal spacers, and did not mandate MRI, but did use
fiducial markers).18 Although rectal spacers have been
shown to reduce rectal toxicity, recent results from the
Prostate Advances in Comparative Evidence, arm B trial
demonstrated very low rates of rectal toxicity without the
use of a rectal spacer.14 Thus, the net benefit of a rectal
spacer is not justified during a pandemic unless simulta-
neously placing fiducial markers with the patient under
local anesthesia.
There was unanimous consensus that if treatment
needs to be performed during the peak of the pandemic,
brachytherapy is not recommended given its reliance on
anesthesia staff and PPE. However, if brachytherapy can
be performed with use of local anesthesia, this may be a
suitable option for those experienced with this method
and if resources are available.
There was also unanimous consensus that once re-
strictions have been removed, radiation therapy of any form
can be delivered. However, it is important to remain
cognizant that additional waves of the pandemic may occur
and restrictions may be reinstated. Thus, using shorter
courses of radiation therapy may still be necessary.Palliative care
This review does not discuss the use of palliative ra-
diation therapy because often this is not necessarily
tumor-type specific (eg, bone metastases, spinal cord
6 N.G. Zaorsky et al Advances in Radiation Oncology: --- 2020compression, bleeding). The same principles of the RADS
framework apply, and the variable efficacy of palliative
radiation therapy should be weighed against the risks of
bringing patients in for radiation therapy, alternative
treatment options (oral analgesics), use of radiation ther-
apy to avoid treatments that may cause even greater
exposure (surgery), or immunosuppression (systemic
therapy).Discussion
Prostate cancer is the most common cancer in men
worldwide and one of the most common cancers treated
within radiation oncology departments.3 The proportion
of patients with prostate cancer receiving radiation ther-
apy continues to expand; it is now used commonly for
definitive treatment of localized and locally advanced
disease, adjuvant and salvage treatment postsurgery,
oligometastatic-directed radiation therapy, and treatment
of the primary in low-volume metastatic disease.4
Furthermore, the complexity of treatment of prostate
cancer has increased with more frequent use of advanced
imaging, including MRI and molecular positron emission
tomography imaging, image guidance with fiducial
markers, and rectal spacers, most of which require extra
procedures or visits and some of which require extra use
of PPE. Thus, patients with prostate cancer represent an
important population that radiation oncology departments
need to efficiently manage in times when resources are
limited.
Patients with prostate cancer are somewhat unique
(other than patients with breast cancer); not only is
prognosis generally favorable, but for patients with more
aggressive disease, the use of ADT can safely delay the
need to start radiation therapy for multiple months. For
this reason, delaying radiation therapy is almost always
safe.
Prostate cancer is also unique in that it is one of the
few cancers we treat with curative intent where radiation
therapy has a survival advantage.19 Very few cancers
have randomized evidence from a single trial that dem-
onstrates radiation therapy improves survival. In other
cancers with worse prognosis, such as pancreatic cancer,
radiation therapy has questionable survival impact. Thus,
excessive delay of radiation therapy in patients with
aggressive prostate cancer should be avoided.
Additionally, although ADT has been safely used for
extended periods neoadjuvantly, it must be recognized
that prolonged courses of neoadjuvant ADT do not pro-
vide oncologic benefit8 and can contribute to excessive
morbidity and even mortality.10-12 Thus, the benefit from
receiving radiation therapy (large) must be balanced with
the impact of delays in treatment start (small), excessive
use of ADT (variable), and risk of infection and
morbidity/mortality from COVID-19.The group agreed that there are variable levels of ev-
idence to support ultra- and moderate hypofractionation in
localized and recurrent disease and that no randomized
trial has demonstrated that altering field size or fraction-
ation or using extreme dose escalation has affected overall
survival. Thus, in the setting of a pandemic where mor-
tality from COVID-19 is possible, the shortest safe
regimen should be used and is unlikely to affect long-term
survival.
These recommendations are not formal rules or pol-
icies; we do not believe this is possible when data are so
limited. Rather, the goal was to provide guidance and a
framework of thinking in the way numerous programs are
approaching the care of patients with prostate cancer at
their own clinics, all of which are experiencing various
stages of impact and restrictions due to the COVID-19
global pandemic. We recommend that you follow your
institutional, state, and federal recommendations when
available to best manage your patients in your own
practice.
Supplementary data
Supplementary material for this article can be found at
https://doi.org/10.1016/j.adro.2020.03.010.
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